HeyJaredScott Harris
- Indexed articles, last 90 days
- 12
- Latest publication
- Oct 1, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Aug 6, 2026
Latest articles
Upadacitinib and Phototherapy Effective for Vitiligo (opens the original)
Read excerpt
Upadacitinib (Rinvoq, AbbVie) was safe and efficacious out to 76 weeks in patients with nonsegmental vitiligo (NSV), with 28-week data showing efficacy further boosted by the addition of ultraviolet B (UVB) phototherapy. New results from two ongoing pivotal phase 3 trials were presented October 1 at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna. Upadacitinib was approved by the European Commission in July for the treatment of adolescents and adults 12 years a
Rheumatology Groups Push Back on Proposed Physician Pay Cuts (opens the original)
Read excerpt
The American College of Rheumatology (ACR) is responding to proposed federal payment cuts its leaders say could undermine rheumatologists’ ability to care for patients — and even imperil practices. The Centers for Medicare & Medicaid Services (CMS) called in July for a 50% payment cut when physicians provide a separately identifiable evaluation and management (E/M) visit on the same day as most procedures are performed. The proposal applies to visits billed as modifier 25 when performed on the s
FDA Grants Priority Review for Diabetic Foot Ulcer Therapy (opens the original)
Read excerpt
The FDA has granted priority review to a Biologics License Application (BLA) for SkinTE, a novel wound-healing therapy used for the treatment of Wagner Grade 1 diabetic foot ulcers. The FDA assigned a target action date of March 16, 2027, the manufacturer, PolarityBio, said in a press release. SkinTE (autologous cutaneous multicellular units) is manufactured from a small piece of healthy full-thickness skin harvested from the patient and applied expeditiously to the wound to maintain cellular vi
FDA Grants Priority Review to Zasocitinib for Psoriasis (opens the original)
Read excerpt
The FDA has accepted a new drug application under priority review for zasocitinib, an oral, once-daily tyrosine kinase 2 (TYK2) inhibitor, for the treatment of moderate-to-severe plaque psoriasis in adults, according to the manufacturer. A regulatory decision is expected in the first quarter of 2027. The filing was supported by findings from the LATITUDE PsO 3001 and 3002 trials, in which zasocitinib, also known as TAK-279, reached all primary and secondary endpoints, according to a news release
Taking Steps to Reduce Disparities in Womenâs Rheumatic Care (opens the original)
Read excerpt
It is well known that women not only tend to acquire rheumatic and musculoskeletal diseases (RMDs) more frequently than men but also often face disparities in the diagnosis and management of these conditions. But why do these disparities persist in the rheumatologist’s office and beyond, and what are some ways that rheumatologists can help to mitigate them? “The main issue is gender bias,” Loreto Carmona, MD, PhD, a rheumatologist and epidemiologist with the Instituto de Salud Musculoesquelética
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.